- Home
- HFFG vs LCTX Comparison
HFFG vs LCTX Comparison
Compare HFFG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFFG
- LCTX
- Stock Information
- Founded
- HFFG N/A
- LCTX 1990
- Country
- HFFG United States
- LCTX United States
- Employees
- HFFG N/A
- LCTX N/A
- Industry
- HFFG Food Distributors
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HFFG Consumer Discretionary
- LCTX Health Care
- Exchange
- HFFG Nasdaq
- LCTX Nasdaq
- Market Cap
- HFFG 162.4M
- LCTX 165.6M
- IPO Year
- HFFG N/A
- LCTX N/A
- Fundamental
- Price
- HFFG $3.27
- LCTX $0.89
- Analyst Decision
- HFFG
- LCTX Strong Buy
- Analyst Count
- HFFG 0
- LCTX 3
- Target Price
- HFFG N/A
- LCTX $5.67
- AVG Volume (30 Days)
- HFFG 34.9K
- LCTX 432.3K
- Earning Date
- HFFG 08-06-2024
- LCTX 08-08-2024
- Dividend Yield
- HFFG N/A
- LCTX N/A
- EPS Growth
- HFFG N/A
- LCTX N/A
- EPS
- HFFG 0.07
- LCTX N/A
- Revenue
- HFFG $1,160,322,000.00
- LCTX $6,186,000.00
- Revenue This Year
- HFFG N/A
- LCTX N/A
- Revenue Next Year
- HFFG N/A
- LCTX $119.00
- P/E Ratio
- HFFG $44.54
- LCTX N/A
- Revenue Growth
- HFFG N/A
- LCTX N/A
- 52 Week Low
- HFFG $2.46
- LCTX $0.77
- 52 Week High
- HFFG $5.91
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- HFFG 49.97
- LCTX 47.03
- Support Level
- HFFG $3.08
- LCTX $0.83
- Resistance Level
- HFFG $3.31
- LCTX $0.90
- Average True Range (ATR)
- HFFG 0.21
- LCTX 0.05
- MACD
- HFFG -0.01
- LCTX 0.00
- Stochastic Oscillator
- HFFG 32.20
- LCTX 35.31
About HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The Company's business consists of one operating segment; HF Group, which operates solely in the United States. The Company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.